Report Code: TIPRE00003533
| No. of Pages:
| Category: Pharmaceuticals
| Status: Prebook
No. of Pages 150
The high potency active pharmaceutical ingredients are highly effective even in small amount. The HPAPIs target specific abnormal cells and destroys them. Hence, they are used in the drugs prescribed for the treatment of chronic diseases. The importance of API manufacturers in the pharmaceutical industry is changing as a result of new customer demands and increasing pressures from global competitors, which is offering lucrative opportunities for the market. With regard to entrance obstacles, regulatory constraints, large investments, and knowledge-related to APIs and HPAPI development, manufacturers with different experiences are making significant investments in HPAPI capabilities.
The growth of the high potency APIs market is majorly attributed to the growing demand for antibody-drug conjugates, rising prevalence of cancer, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. Moreover, the growing adoption of HPAPI in different applications and the high growth in cancer therapeutics would supplement market growth during the forecast period. However, dearth of skilled professionals is hampering the growth of the market.
The “Global High Potency APIs market Forecast to 2028” report aims to provide an overview of the high potency APIs ( market with detailed market segmentation based on type, type of synthesis, manufacturer, and therapeutic application. The report provides key market statistics based on the performances of the leading players. It also offers key trends and opportunities in the market.
|Market Size Value in||US$ 22.74 billion in 2021|
|Market Size Value by||US$ 42.65 billion by 2028|
|Growth rate||CAGR of 9.4% from 2022 to 2028|
|No. of Pages||150|
|Historical data available||Yes|
|Segments covered||Type, Type of Synthesis, Manufacturer, and Therapeutic Application|
|Regional scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Country scope||US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The global high potency APIs market is segmented on the basis of type, type of synthesis, manufacturer, and therapeutic application. Based on type, the market is bifurcated into generic and innovative. Based on type of synthesis, the market is segmented into synthetic and biotech. Based on manufacturer, the high potency APIs ( market Is segmented into in-house and outsourced. By therapeutic application, the market is segmented into oncology, hormonal imbalance, glaucoma, and others.
The global high potency APIs market is segmented into five major regions—North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The report covers analysis and forecast of 18 countries across the world along with trends and opportunities prevailing in the region. From the regional perspective, North America dominated the market with ~35% share in 2021. The market growth in the region is majorly attributed to the presence of prominent manufacturers and advanced technological infrastructure. Additionally, the high prevalence of chronic diseases, such as cancers, in the region is driving the market growth. The below figure shows the revenue growth trend in the global high potency APIs ( market:
The report analyzes factors, such as drivers, restraints, opportunities, and future trends, which impact the high potency APIs market. It also provides an exhaustive Porter's five forces analysis of the factors influencing the market.
The high-potency APIs/HPAPI market suffered during the COVID-19 pandemic due to disrupted supply chain. China and India are the two countries where most API is produced. In 2020, according to the Germany Trade & Invest (GTAI), around 60% of the world's APIs, particularly high-potency APIs, are made in China or India, and 18% of the generic medicine production market worldwide is accounted for by India alone. The majority of this produced medicines are exported to other nations. Also, 70% of India's generics industry's APIs, particularly high-potency APIs, are produced in China, a significant manufacturing hub. These countries were the most affected by the pandemic, which hindered the market growth. However, due to rising cases of COVID-19, and many countries approved the use of antiviral drugs with high potency molecules. For example, remdesivir has been approved for COVID-19 treatment. The overall high-potency APIs/HPAPI market was adversely affected during the COVID-19 Pandemic.
The report covers key developments in the high potency APIs market. Various companies are focusing on organic growth strategies, such as product launches, product approvals, patents, and events. Inorganic growth strategies such as acquisitions, partnerships, and collaborations have encouraged the expansion of business and the customer base of market players. The market players are anticipated to experience lucrative growth opportunities in the coming years due to the rising demand for high potency APIs ( products.
The report also includes the profiles of key high potency APIs market companies, along with their SWOT analysis and market strategies. In addition, it focuses on leading industry players’ information such as company profiles, components and services offered, financial information for the last three years, and key development in the past five years. The list of a few companies engaged in the high potency APIs ( market is mentioned below:
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
The List of Companies